Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy.
Trends Cancer
; 3(7): 529-541, 2017 07.
Article
em En
| MEDLINE
| ID: mdl-28718406
ABSTRACT
Hypoxia (low O2) is a pathobiological hallmark of solid cancers, resulting from the imbalance between cellular O2 consumption and availability. Hypoxic cancer cells (CCs) stimulate blood vessel sprouting (angiogenesis), aimed at restoring O2 delivery to the expanding tumor masses through the activation of a transcriptional program mediated by hypoxia-inducible factors (HIFs). Here, we review recent data suggesting that the efficacy of antiangiogenic (AA) therapies is limited in some circumstances by HIF-dependent compensatory responses to increased intratumoral hypoxia. In lieu of this evidence, we discuss the potential of targeting HIFs as a strategy to overcome these instances of AA therapy resistance.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Inibidores da Angiogênese
/
Fatores de Transcrição Hélice-Alça-Hélice Básicos
/
Inibidores da Topoisomerase
/
Neoplasias
/
Neovascularização Patológica
Limite:
Humans
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article